TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17089229

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg before incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline before incision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline before incision, Ketamine 0.4 mg/kg after incision
Number of subjects: 60
Study: 15689053

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 11508042

Group type: EXPERIMENTAL
Intervention: Social skills training program
Number of subjects: 315

Group type: COMPARATOR
Intervention: No social skills training
Number of subjects: 315
Study: 9252161

Group type: EXPERIMENTAL
Intervention: Ribavirin 600 mg given orally twice daily for 36 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 59
Study: 8511910

Group type: EXPERIMENTAL
Intervention: Postoperative TPN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative TPN
Number of subjects: 0
Study: 2891285

Group type: EXPERIMENTAL
Intervention: Ionic contrast agent (sodium meglumine diatrizoate)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nonionic contrast agent (iopamidol)
Number of subjects: 34
Study: 29476444

Group type: EXPERIMENTAL
Intervention: Upward dose titration of pregabalin
Number of subjects: 2642

Group type: COMPARATOR
Intervention: No upward dose titration (inadequately titrated patients)
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Patient satisfaction with tolerability
Number of subjects: 2642
Study: 26447636

Group type: COMPARATOR
Intervention: CAF+CTG (Control Group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CAF+PRF (Intervention Group)
Number of subjects: 24
Study: 25371633

Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab followed by grid laser treatment (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab followed by grid laser treatment (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Grid laser alone (Group 3)
Number of subjects: 30
Study: 22228125

Group type: EXPERIMENTAL
Intervention: Chronic cerebrospinal venous insufficiency (CCSVI) detection in MS patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 20925997

Group type: EXPERIMENTAL
Intervention: Metformin with clomiphene citrate (CC) and human menopausal gonadotrophin (HMG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with clomiphene citrate (CC) and human menopausal gonadotrophin (HMG)
Number of subjects: 60
Study: 18616656

Group type: EXPERIMENTAL
Intervention: AST‐120
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 16115974

Group type: EXPERIMENTAL
Intervention: Propofol‐Lipuro
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 60
Study: 11954953

Group type: EXPERIMENTAL
Intervention: Flecainide (200mg, n=12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (0.2 mg/kg, n=9)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 30
Study: 9892882

Group type: EXPERIMENTAL
Intervention: THC (10 mg/m2 of body surface area)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7740291

Group type: EXPERIMENTAL
Intervention: 100 mg ASA orally daily (Group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated controls (Group B)
Number of subjects: 27
Study: 1338091

Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy with sigmoid resection (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polyglycolic acid mesh rectopexy without sigmoidectomy (Group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 6586277

Group type: EXPERIMENTAL
Intervention: AMSA Regimen I (120 mg/m2/day for 5 days)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: AMSA Regimen II (60 mg/m2/day for 10 days)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: AMSA Regimen I (for ANLL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: AMSA (both regimens combined for ALL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: AMSA (for ANLL)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: AMSA (first course)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: AMSA
Number of subjects: 104
Study: 30565741

Group type: EXPERIMENTAL
Intervention: Zoledronate-coated implant
Number of subjects: 16

Group type: COMPARATOR
Intervention: Uncoated implant (Control)
Number of subjects: 16
Study: 30545301

Group type: EXPERIMENTAL
Intervention: Educational intervention for HCPs including General Practitioners (GP)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Educational intervention for HCPs
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Overall practices (both intervention and control)
Number of subjects: 169
Study: 25086766

Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Comorbid Major Depressive Disorder
Number of subjects: 165

Group type: COMPARATOR
Intervention: African Americans without PTSD
Number of subjects: 165
Study: 21326328

Group type: EXPERIMENTAL
Intervention: Adherence therapy (AT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 136
Study: 19559792

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4mg once a day for a maximum of 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 17446823

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Medical treatment only (Control)
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 1089
Study: 15306666

Group type: EXPERIMENTAL
Intervention: Advanced life support (ALS)
Number of subjects: 5638

Group type: COMPARATOR
Intervention: Rapid defibrillation (control)
Number of subjects: 5638

Group type: EXPERIMENTAL
Intervention: Bystander witnessed arrest
Number of subjects: 5638

Group type: EXPERIMENTAL
Intervention: Bystander CPR
Number of subjects: 5638

Group type: EXPERIMENTAL
Intervention: Rapid defibrillation
Number of subjects: 5638
Study: 11898372

Group type: EXPERIMENTAL
Intervention: Sinusoidal modulated currents (SMC) on the heart area
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Sinusoidal modulated currents (SMC) on the sinocarotid zones
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo procedures
Number of subjects: 137
Study: 9516597

Group type: EXPERIMENTAL
Intervention: Dose-dense paclitaxel-containing therapy (A->T->C regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional regimens
Number of subjects: 0
Study: 7827298

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (300 mg zinc aspartate, equal to 60 mg elemental zinc per day) for 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation
Number of subjects: 14
Study: 3045025

Group type: EXPERIMENTAL
Intervention: Modest sodium (100 mmol/day)/high potassium (130 mmol/day) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal diet (160 mmol Na/day and 80 mmol K/day)
Number of subjects: 0
Study: 30547745

Group type: EXPERIMENTAL
Intervention: Listening to personally-relevant music for 20 minutes every other day for six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25834076

Group type: EXPERIMENTAL
Intervention: Surgical treatment (Group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Regular, ongoing therapy (Group 3)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Botulinum toxin injections (Group 2)
Number of subjects: 39
Study: 23833857

Group type: EXPERIMENTAL
Intervention: Group LVHC: 0.5 ml/kg bupivacaine 0.375% (1.875 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group C: 1 ml/kg bupivacaine 0.25% (2.5 mg/kg)
Number of subjects: 50
Study: 21079463

Group type: EXPERIMENTAL
Intervention: anesthetic spray
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: placebo spray
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: anesthetic intradermal injection
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: placebo intradermal injection
Number of subjects: 84

Group type: COMPARATOR
Intervention: control group with no local anesthetic agent
Number of subjects: 84
Study: 18398105

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE)
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 16632763

Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 6, 12, and 18 months
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 3, 12, and 15 months
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control group (no EC40 varnish)
Number of subjects: 461
Study: 14638334

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon alfa-2b plus ribavirin
Number of subjects: 0
Study: 8843494

Group type: EXPERIMENTAL
Intervention: Inositol (6 gm daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Glucose (placebo)
Number of subjects: 11
Study: 1423178

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and methotrexate (CAM)
Number of subjects: 103
Study: 3865493

Group type: EXPERIMENTAL
Intervention: Cefaclor 20 mg/kg body weight b.i.d. for 10 days
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cefaclor treatment
Number of subjects: 91
Study: 30930801

Group type: EXPERIMENTAL
Intervention: EMDR therapy (n = 71)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 71)
Number of subjects: 142
Study: 28281353

Group type: EXPERIMENTAL
Intervention: Opt-out arm (received a letter stating they were enrolled with the option to opt out)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Opt-in arm (received a standard recruitment letter)
Number of subjects: 569
Study: 27659878

Group type: EXPERIMENTAL
Intervention: Medtronic TYRX absorbable envelope
Number of subjects: 7764

Group type: COMPARATOR
Intervention: No Medtronic TYRX absorbable envelope (Control)
Number of subjects: 7764
Study: 24518774

Group type: EXPERIMENTAL
Intervention: Statin drug use
Number of subjects: 9457

Group type: EXPERIMENTAL
Intervention: Duration of statin use
Number of subjects: 9457
Study: 22388296

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1309
Study: 20698837

Group type: EXPERIMENTAL
Intervention: Homozygous AA subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Heterozygous AG subjects
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alcohol intoxication
Number of subjects: 36
Study: 16953394

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride at a daily dose of 1,500 mg for 12 weeks along with conventional medication
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo for 12 weeks along with conventional medication
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16193895

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 12398260

Group type: EXPERIMENTAL
Intervention: Modafinil 50 mg x 24 h(‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sleep deprivation (SD)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Recovery period after SD
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Modafinil 150 mg x 24 h(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Modafinil 300 mg x 24 h(‐1)
Number of subjects: 6
Study: 9915885

Group type: EXPERIMENTAL
Intervention: SC-FOS 10 g/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SC-FOS 20 g/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: SC-FOS 0 g/d (Control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SC-FOS 2.5 g/d (Control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SC-FOS 5 g/d (Control)
Number of subjects: 40
Study: 7766747

Group type: EXPERIMENTAL
Intervention: Bisacodyl (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactulose (30 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactose (45 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (standard conditions)
Number of subjects: 30
Study: 2271369

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 38177

Group type: EXPERIMENTAL
Intervention: Prednisone (high-dose suppressive therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone (prophylactic dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (high dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (low dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine (general)
Number of subjects: 0
Study: 30626147

Group type: EXPERIMENTAL
Intervention: Comfort meal ingestion in women
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comfort meal ingestion in men
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of meal experience between genders
Number of subjects: 20
Study: 24954156

Group type: EXPERIMENTAL
Intervention: Antidepressant treatments
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Remitted patients
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: 12-month follow-up
Number of subjects: 2280
Study: 24156138

Group type: EXPERIMENTAL
Intervention: 1.5% arginine/Dical/1450 ppm fluoride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5% arginine/calcium carbonate/1450 ppm fluoride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control (Dical and 1450 ppm fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (Dical and 250 ppm fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control (1450 ppm fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (250 ppm fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5% arginine/calcium carbonate/1000 ppm fluoride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control (1000 ppm fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (0 ppm fluoride)
Number of subjects: 0
Study: 21122849

Group type: EXPERIMENTAL
Intervention: Acupoint electrical stimulation (AES) at true acupoints
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupoint electrical stimulation (AES) at sham acupoints
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention with AES (control group)
Number of subjects: 90
Study: 18810547

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7 mmHg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (14 mmHg)
Number of subjects: 140
Study: 16637835

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.3% lomefloxacin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.3% norfloxacin
Number of subjects: 14
Study: 15327586

Group type: EXPERIMENTAL
Intervention: Gelatin-free epoetin alfa (6000 IU per subject)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gelatin-containing epoetin alfa (6000 IU per subject)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gelatin-free epoetin alfa (750 IU per subject)
Number of subjects: 60
Study: 11759309

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 34
Study: 9249269

Group type: EXPERIMENTAL
Intervention: Hypertonic saline‐induced sputum
Number of subjects: 18
Study: 8392345

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH) and Unfractionated heparin (UFH)
Number of subjects: 12
Study: 3440388

Group type: EXPERIMENTAL
Intervention: Lowering blood cholesterol through various recruitment methods (not specified in detail)
Number of subjects: 0
Study: 30871639

Group type: EXPERIMENTAL
Intervention: lambda‐cyhalothrin with pheromone + residual insecticide spray (PI)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: deltamethrin with dog collars (DC)
Number of subjects: 788

Group type: COMPARATOR
Intervention: no insecticide (C)
Number of subjects: 788
Study: 29534330

Group type: EXPERIMENTAL
Intervention: Liquid micelles (500 mg vineatrol, 30 mg trans-resveratrol, 75 mg trans-ε-viniferin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Native powder (500 mg vineatrol, 30 mg trans-resveratrol, 75 mg trans-ε-viniferin)
Number of subjects: 12
Study: 27137199

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 international units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23434570

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week plus methotrexate 7.5 mg/week (increased to 20 mg/week within 2 months) and intra-articular triamcinolone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Methotrexate plus placebo-adalimumab and intra-articular triamcinolone
Number of subjects: 180
Study: 22610520

Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Chest tube and talc slurry pleurodesis (talc)
Number of subjects: 106
Study: 19596331

Group type: EXPERIMENTAL
Intervention: Lipoprotein components (LC), specifically non-high density cholesterol (nHDL-C)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Lipoprotein components (LC)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Traditional risk factors (serum creatinine, diabetes, inflammation measured by C-reactive protein)
Number of subjects: 1734
Study: 17703897

Group type: EXPERIMENTAL
Intervention: Prior aware participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serendipitously aware participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unaware participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serendipitously aware group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior aware group
Number of subjects: 0
Study: 16470487

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 181

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 181
Study: 11772845

Group type: EXPERIMENTAL
Intervention: Cluster randomised studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quasi-experimental designs
Number of subjects: 0
Study: 10365000

Group type: EXPERIMENTAL
Intervention: Midwife top-ups (group MW, n = 43)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (group PCEA, n = 44)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Continuous infusion (group Cl, n = 46)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Continuous infusion (group Cl)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Midwife top-ups (group MW)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (group PCEA)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 133
Study: 7554701

Group type: EXPERIMENTAL
Intervention: 2400 mg/day felbamate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2201727

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study: 7261663

Group type: EXPERIMENTAL
Intervention: Topical thrombin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no topical thrombin)
Number of subjects: 102
Study: 30629046

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg body mass)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 28486692

Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1 (CS)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin/S-1 (DCS)
Number of subjects: 132
Study: 26427562

Group type: EXPERIMENTAL
Intervention: Contextually-tailored intervention delivered by trained health coaches using advanced geographic information system tools, linking families to community resources, with support modalities including text messages and virtual visits over a one-year period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced pediatric care plus non-tailored health coaching (Control group).
Number of subjects: 0
Study: 23812464

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Ibandronate (150 mg orally every month)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 833

Group type: COMPARATOR
Intervention: Ibandronate
Number of subjects: 833
Study: 20884788

Group type: EXPERIMENTAL
Intervention: Point-of-care biomarker panel assessment
Number of subjects: 2243
Study: 19111476

Group type: EXPERIMENTAL
Intervention: Locked clavicle reconstruction plate in anterior-inferior position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nonlocked clavicle reconstruction plate in anterior-inferior position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Locked clavicle reconstruction plate in superior position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nonlocked clavicle reconstruction plate in superior position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Superior plates (locked and nonlocked)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anterior-inferior plates
Number of subjects: 24
Study: 17725176

Group type: EXPERIMENTAL
Intervention: 500 mg probenecid 3 times daily for 2 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7